37 results about "Chronic rhinosinusitis" patented technology

Disclosed are methods and apparatus for safe, simple and effective broad-spectrum treatments of chronic rhinosinusitis and other common and less common infections of the sino-nasal tract which may implicate not only a wide range of bacterial species but also fungi and viruses. Electromagnetic radiative energy including visible, and optionally, thermal RF, microwave or other longer wavelengths, is applied to target internal surfaces of the sino-nasal tract to destroy or incapacitate superficial microorganisms without the use of antibiotics. The treatment can be controlled to permit regrowth of healthy microflora. A handheld energy applicator has a light output head receivable into, or engageable with, the treatment subject's nostril which may be provided with extensions to reach the sinuses. Useful embodiments of the invention include pretreatment of target sino-nasal surfaces with a photosensitizing agent such as an oxidizing agent or a complementary stain. For example methylene blue can be used with orange or red light. The combination treatment of photosensitizer and application of visual wavelength energy provides a flexible treatment regimen which enables low concentrations of stains to be employed, minimizing aesthetic problems.

Chronic rhinosinusitis and other bacterial sinus conditions may be treated by applying a solvating system containing a surfactant to a bacterial biofilm in a nasal or sinus cavity, disrupting the biofilm, and applying a protective layer of a polymeric film-forming medical sealant.

Method for treating chronic rhinosinusitis in a human patient. In the method a photosensitizing agent such as indocyanine green can be applied to color a nasal or sinal treatment site harboring infectious microorganisms. The photosensitizing agent can have an energy absorption peak in a near infrared wavelength region of the electromagnetic spectrum. The method can also include applying light energy from a laser source at a near infrared wavelength or wavelengths to the colored treatment site, for a duration sufficient to control the microorganisms. Apparatus for performing the method is also disclosed.

The invention provides methods and compositions for the prevention and treatment of Siglec-8 associated diseases such as chronic rhino sinusitis with concomitant asthma and aspirin-exacerbated respiratory disease. In particular, the invention provides methods for the prevention and treatment of Siglec-8 associated diseases through administration of antibodies or agonists that bind to human Siglec-8 or compositions comprising said antibodies or agonists. The invention also provides articles of manufacture or kits comprising antibodies or agonists that bind to human Siglec-8 for the prevention and treatment of Siglec-8 associated diseases such as chronic rhinosinusitis with concomitant asthma and aspirin-exacerbated respiratory disease.

Provided is a composition for preventing, ameliorating, or treating inflammatory diseases, the composition including, as active ingredients, lactic acid bacteria-derived extracellular vesicles isolated from culture fluid of lactic acid bacteria; and a method for diagnosing atopic dermatitis. The composition including the lactic acid bacteria-derived extracellular vesicles as active ingredients is expected to be usefully used in development of drugs, cosmetics, or health functional food for preventing, ameliorating, or treating inflammatory diseases such as atopic dermatitis, chronic rhinitis, chronic rhinosinusitis, asthma, chronic obstructive pulmonary disease, sepsis, etc. Also, the composition will be usefully used for diagnosis of atopic dermatitis by measuring the distribution of lactic acid bacteria-derived extracellular vesicles in a urine or blood sample.

The invention discloses a Chinese medicinal preparation for treating chronic rhinosinusitis, which is characterized by being prepared from the following raw Chinese medicinal herbs in percentage by weight, 6.7-10.2 % of magnolia flower, 6.7-10.2 % of dark plum, 3.4-6.8 % of dahurian angelica root, 6.7-10.2 % of siberian cocklour fruit, 15.3-18.6 % of astragalus root, 6.7-10.2 % of chrysanthemum, 6.7-10.2 % of Chinese thorowax root, 3.4-6.8 % of cicada slough, 3.4-6.8 % of honey-fried Chinese ephedra, 6.8-10.2 % of honey-fried licorice root, 6.8-10.2 % of paniculate swallowwort root and 6.8-10.2 % of India madder root. The Chinese medicinal preparation for treating chronic rhinosinusitis has the advantages of reasonable formulation, convenience for taking, no toxic or side effects, has thefunctions of increasing immunity, shortening the curing time for chronic rhinosinusitis and improving a therapeutic effect, and can be widely used for treating the chronic rhinosinusitis.

The present invention provides a method for identifying bacterial induced rhinosinusitis. The method comprises obtaining a nasal or paranasal mucus sample and detecting the presence of neutrophil degranulation in the mucus sample. Degranulation of neutrophils can be determined by morphological analysis of the cells in the mucus or by detection of released (i.e., “free”) granule content markers such as neutrophil elastase or myeloperoxidase. Based on an accurate determination of the cause of sinusitis as described herein, an appropriate treatment can be instituted.

Compounds represented by formula (I) and the formula (IV) have an inhibitory activity of MMP-9 production, therefore, are useful as a medicine agent with fewer side effects than conventional MMP enzyme activity inhibitors, as a prophylactic and therapeutic drug for oncogenic angiogenesis, chronic rheumatoid arthritis, vascular intimal thickening after a percutaneous coronary transluminal angioplasty, vascular atherosclerosis, hemorrhagic apoplexy, acute myocardial infarction, chronic heart failure, aneurysm, lung cancer metastasis, adult respiratory distress syndrome, asthma, interstitial pulmonary fibrosis, chronic rhinosinusitis, bronchitis or chronic obstructive pulmonary disease (COPD).

The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of nasal rhinitis, nasal sinusitis, chronic rhinosinusitis, and nasal polyposis. More particularly, the invention provides methods, including broadly the critical dosage ranges of rhCC10 and intranasal route of administration, which may be administered to safely and effectively treat the aforementioned conditions. The invention further provides a composition useful in administering rhCC10 to humans.

A novel humanized anti-IgE antibody is disclosed. The antibody is capable of binding to free IgE, membrane-bound IgE on B lymphocytes, IgE bound by CD23, but not to IgE bound by high-affinity IgE.Fc receptor on mast cells. The present invention relates to the treatment of IgE-mediated diseases, including allergic asthma, allergic rhinitis, atopic dermatitis, food allergy, chronic spontaneous (idiopathic) urticaria, chronic rhinosinusitis, systemic mastocytosis, cutaneous mastocytosis, allergic bronchopulmonary aspergillosis, recurrent idiopathic angioedema, and eosinophil-associated gastrointestinal disorder by administering the anti-IgE antibody of the present invention.

The invention discloses a traditional Chinese medicine preparation for treating chronic rhinosinusitis and a preparation method thereof. The preparation comprises the following parts by weight: 1-2 parts of Houttuynia cordata, 1-2 parts of Scutellaria baicalensis, and 1-2 parts of pepper. The raw materials of traditional Chinese medicine are mixed in proportion, the fat-soluble components in the medicinal material are extracted, and then the required medicinal dosage form is prepared according to a conventional method. In the traditional Chinese medicine preparation for treating chronic rhinosinusitis of the present invention, the spicy medicine capsicum is creatively introduced, which is scientifically compatible with other traditional Chinese medicines, and has good therapeutic effect and less side effects.

The invention relates to a medicament, in particular to a medicament for treating chronic rhinosinusitis, which is prepared from many traditional Chinese medicines serving as raw materials. The invention mainly solves the problems of serious side effects, susceptibility to causing medicament resistance, undesirable treatment effect, incapability of suppressing relapse and the like of the conventional medicaments for treating chronic rhinosinusitis. The medicament of the invention is prepared by proportioning Chinese ligusticum rhizome, biond magnolia flower, thunberg fritillary bulb, pseudo-ginseng, dendrobe, coasiaI gIehnia root, bunge cherry seed, scrophularia ningpoensis, dwarf lilyturf tuber, fragrant solomonseal rhizome, the root of Chinese thorowax, indigowoad leaf, scaphium scaphigerum, Scutellaria baicalensis, rough gentian, indigo naturalis, liquoric root, talcum powder, asiatic moonseed rhizome, blackberry lily, Platycodon grandiflorum, mint, hawthorn, bombyx batryticatus, great burdock achene, mongolian snakegourd root, Chinese date and ginger. In the invention, the traditional Chinese medicines are used for treatment and conditioning, so the side effects are fewer, medicament resistance is not generated in a taking process, both the symptoms and root causes are address, the treatment effect is remarkable, the cure rate is high, surgery is not needed, and extra injury to the patient is avoided.